Improving on success: What treating the urban poor in America can teach us about improving antiretroviral programmes in Africa

AIDS

Volumn 18, Issue SUPPL. 3, 2004, Pages

  Amoroso, Anthony ^a,b   Spencer, Derek E ^a   Redfield, Robert R ^a  

^a UNIVERSITY OF MARYLAND SCHOOL OF MEDICINE   (United States)

^b INSTITUTE OF HUMAN VIROLOGY   (United States)

Author keywords

Adherence; Antiretroviral therapy; Directly; HIV; Observed Therapy; Treatment support

Indexed keywords

ANTIRETROVIRUS AGENT;

ADULT; AFRICA; ARTICLE; CONTROLLED STUDY; DRUG SELF ADMINISTRATION; EPIDEMIC; FEMALE; HEALTH CARE COST; HEALTH EDUCATION; HEALTH PROGRAM; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; MAJOR CLINICAL STUDY; MALE; OBSERVATION; POVERTY; PRIORITY JOURNAL; TREATMENT FAILURE; TREATMENT OUTCOME; TREATMENT PLANNING; UNITED STATES; URBAN POPULATION; VIRUS INHIBITION;

ADULT; ANTIRETROVIRAL THERAPY, HIGHLY ACTIVE; CAREGIVERS; DIRECTLY OBSERVED THERAPY; FEMALE; HIV INFECTIONS; HUMANS; MALE; MIDDLE AGED; PATIENT COMPLIANCE; PROGRAM EVALUATION; TREATMENT OUTCOME; URBAN HEALTH; URBAN HEALTH SERVICES;

EID: 3843059034     PISSN: 02699370     EISSN: None     Source Type: Journal    
DOI: 10.1097/00002030-200406003-00008     Document Type: Article

References (18)

1. Richman DD, Bozzetti S, Morton S, Chien S, Wrin T, Dawson K, Hellmann N. The prevalence of antiretroviral resistance in the US. In: 41st Interscience Conference on Antimicrobial Agents and Chemotherapy. Chicago, 18 December 2001 [Abstract LB17].
2. Little SJ, Holte S, Routy JP, Daar ES, Markowitz M, Collier AC;. Antiretroviral-drug resistance among patients recently infected with HIV. N Engl J Med 2002, 347:385-394.
3. Hughes MD, Johnson VA, Hirsch MS, Bremer JW, Elbeik T, Erice A. Monitoring plasma HIV-1 RNA levels in addition to CD4+ lymphocyte count improves assessment of antiretroviral therapeutic response. ACTG 241 Protocol Virology Substudy Team. Ann Intern Med 1997, 126:929-938.
4. Hirsch MS, Brun-Vézinet F, D'Aquila RT, Hammer SM, Johnson VA, Kuritzkes DR. Antiretroviral drug resistance testing in adult HIV-1 infection: recommendations of an International AIDS Society-USA Panel. JAMA 2000, 283:2417-2426.
5. Karon JM, Fleming PL, Steketee RW, De Cock KM. HIV in the United States at the turn of the century: an epidemic in transition. Am J Public Health 2001, 91:1060-1068.
6. Moore RD, Chaisson RE. Natural history of HIV infection in the era of combination antiretroviral therapy. AIDS 1999, 13:1933-1942.
7. Lucas GM, Chaisson RE, Moore RD. Highly active antiretroviral therapy in a large urban clinic: risk factors for virologic failure and adverse drug reactions. Ann Intern Med 1999, 131:81-87.
8. Deeks SG, Hecht FM, Swanson M, Elbeik T, Loftus R, Cohen PT, Grant RM. HIV RNA and CD4 cell count response to protease inhibitor therapy in an urban AIDS clinic: response to both initial and salvage therapy. AIDS 1999, 13 (Suppl.):F35-F43.
9. Casado JL, Perez-Elias MJ, Marti-Belda P, Antela A, Suarez M, Ciancas E, et al. Predictors of long-term response to protease inhibitor therapy in a cohort of HIV-infected patients. AIDS 1998, 12 (Suppl.):F131-F135.
10. Ledergerber B, Egger M, Opravil M, Telenti A, Hirschel B, Battegay M. Clinical progression and virological failure on highly active antiretroviral therapy in HIV-1 patients: a prospective cohort study. Swiss HIV Cohort Study. Lancet 1999, 353:863-868.
11. Lucas GM, Chaisson RE, Moore RD. Survival in an urban HIV-1 clinic in the era of highly active antiretroviral therapy: a 5-year cohort study. J Acquired Immune Defic Syndr 2003, 33:321-328.
12. Chen RY, Westfall AO, Mugavero MJ, Cloud GA, Raper JL, Chatham AG. Duration of highly active antiretroviral therapy regimens. Clin Infect Dis 2003, 37:714-722.
13. Del Rio C, Green S, Abrams C, Lennox J. From diagnosis to undetectable: the reality of HIV/AIDS care in the inner city. In: Program and abstracts of the 8th Conference on Retroviruses and Opportunistic Infections. Chicago, IL, 4-8 February 2001 [Abstract S21].
14. Thiebaut R, Morlat P, Jacqmin-Gadda H, Neau D, Merci P, Dabis F, Chene G. Clinical progression of HIV-1 infection according to the viral response during the first year of antiretroviral treatment. Groupe d'Epidemiologie du SIDA en Aquitaine (GECSA). AIDS 2000, 14:971-978.
15. Paterson DL, Swindells S, Mohr J, Brester M, Vergis EN, Squier C, et al. Adherence to protease inhibitor therapy and outcomes in patients with HIV infection. Ann Intern Med 2000, 133:21-30.
16. Fischl M, Castro J, Monroig R, Scerpella E, Thompson L, Rechtime D, Thomas D. Impact of directly observed therapy on long-term outcomes in HIV clinical trials. In: Program and abstracts of the 8th Conference on Retroviruses and Opportunistic Infections. Chicago, IL, 4-8 February 2001 [Abstract 528].
17. Dybul M, Bolan R, Condoluci D, Cox-Iyamu R, Redfield R, Hallahan CW. Evaluation of initial CD4+ T cell counts in individuals with newly diagnosed human immunodeficiency virus infection, by sex and race, in urban settings. J Infect Dis 2002, 185:1818-1821.
18. Dybul M, Chun TW, Yoder C, Hidalgo B, Belson M, Hertogs K. Short-cycle structured intermittent treatment of chronic HIV infection with highly active antiretroviral therapy: effects on virologic, immunologic, and toxicity parameters. Proc Natl Acad Sci USA 2001, 98: 15161-15166.